Genomic Health, Inc. (GHDX) Tops Q4 EPS by 3c, Guides FY13
Genomic Health, Inc. (NASDAQ: GHDX) reported Q4 EPS of $0.06, $0.03 better than the analyst estimate of $0.03. Revenue for the quarter came in at $60.4 million versus the consensus estimate of $58.9 million.
Genomic Health, Inc. sees FY2013 revenue of $258-266 million, versus the consensus of $262.40 million.
Genomic Health, Inc. sees FY2013 revenue of $258-266 million, versus the consensus of $262.40 million.
For earnings history and earnings-related data on Genomic Health, Inc. (GHDX) click here.